HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consumer Division Divestments Would Spotlight Firms’ Value – Analysts

This article was originally published in The Tan Sheet

Executive Summary

Germany’s Merck KGaA could join the ranks of firms like Pfizer potentially looking to leave the consumer health care product business, market analysts argue.

You may also be interested in...



Abbott Nutritionals Rise In Stature With Departure Of Branded Rx

Abbott Laboratories’ nutrition business – one of four divisions in the remaining diversified medical products firm – gains importance with the firm’s plan to spin off its research-based branded pharmaceuticals business.

Abbott Says Nutritionals Can Succeed Without M&A Activity

Abbott Laboratories executives say its nutritionals business is staying put and can succeed without mergers and acquisitions, despite dragging U.S. sales.

WIC Appropriations Woes Threaten Branded Formula Supremacy

Proposed appropriations cuts could threaten branded infant formulas’ strong competitive advantages.

Related Content

Topics

UsernamePublicRestriction

Register

RS134372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel